ClinicalTrials.gg
CompletedNCT07295951Updated Sep 25, 2026

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

A Phase 1 interventional study of 14C-bleximenib and bleximenib in Acute Lymphoblastic Leukemia, Acute Leukemias and Acute Myeloid Leukemia, sponsored by Janssen Research & Development, LLC. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Updated Sep 25, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United Kingdom — 17 open to participants now, 22 under way, 4 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United Kingdom.

Enrollment
80th of 83
6 · median 85
Started
2025
with 4 others
Phase 1
11 of 98
2 open now
Registered
97th of 98
by date

Among the 98 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United Kingdom, this one is the 80th largest by enrollment of the 83 interventional ones that give a count, is one of 5 that started in 2025, is one of 11 in phase 1, and was the 97th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

17 of the 98 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United Kingdom are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).

03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Acute Leukemias
  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight greater than or equal to (>=) 40 kilograms (kg)
  • (R/R) acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A), nucleophosmin 1 (NPM1), nucleoporin 98 (NUP98) or nucleoporin 214 (NUP214) gene alterations, and has exhausted, or is ineligible for available therapeutic options
  • (ECOG) performance status grade of 0 or 1
  • Regular bowel movements (that is [i.e.], average production of at least one stool every 2 days)
  • A woman of must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment

Exclusion criteria

Exclusion criteria:

  • Acute promyelocytic leukemia or diagnosis of Down syndrome associated leukemia, according to world health organization (WHO) 2016 criteria
  • Active central nervous system (CNS) disease
  • Recipient of solid organ transplant
  • Any toxicity (except for alopecia, stable peripheral neuropathy, thrombocytopenia, neutropenia, anemia) from previous anticancer therapy that has not resolved to baseline or to Grade 1 or less
  • Major surgery (e.g., requiring general anesthesia) within 2 weeks prior to first dose of study treatment or has not recovered from surgery or has major surgery planned during the time the participant is receiving study treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Bleximenib

    Participants will receive a single oral dose of 14C-bleximenib on Cycle 1 Day 1. The recommended Phase 2 dose (RP2D) of bleximenib will start on Cycle 1 Day 2 with non-radiolabeled bleximenib and will continue until the end of Cycle 1 (cycle duration=28 days), with subsequent roll-over for eligible participants to 75276617ALE1001 (NCT04811560) for continued non-radiolabeled bleximenib administration as appropriate.

    Drug: 14C-bleximenib · Drug: bleximenib

Interventions

  • 14C-bleximenib will be administered orally.

    Also known as: JNJ-75276617

  • Non-radiolabeled bleximenib will be administered orally.

    Also known as: JNJ-75276617

06

What researchers measure

Primary outcomes

  1. Percentage of Dose Excreted in Urine (feu)

    Total amount excreted into the urine, expressed as a percentage of the administered dose will be reported.

    Time frame: Up to Day 28

  2. Percentage of Dose Excreted in Feces (fef)

    Total amount excreted into the feces expressed as a percentage of the administered dose will be reported.

    Time frame: Up to Day 28

  3. Amount Excreted in Urine (Aeu)

    Aeu defined as the total amount of bleximenib and radioactivity excreted into the urine will be reported.

    Time frame: Up to Day 28

  4. Amount Excreted in Feces (Aef)

    Aef defined as the total amount of bleximenib and radioactivity excreted into the feces will be reported.

    Time frame: Up to Day 28

  5. Area Under the Concentration-Time Curve from Time 0 to the Last Measurable Concentration (AUC0-t)

    AUC0-t in whole blood and plasma will be reported.

    Time frame: Cycle 1 Day 1, and Cycle 1 Day 2 (Cycle duration=28 days)

  6. Maximum Observed Concentration (Cmax)

    Maximum observed concentration in whole blood and plasma will be determined.

    Time frame: Cycle 1 Day 1, and Cycle 1 Day 2 (Cycle duration=28 days)

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the study treatment. A SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.

    Time frame: Up to 58 days

07

Study locations

1 site
  • The Christie NHS Foundation Trust Christie Hospital
    Manchester, M20 4BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Jul 2026, 8 months.

Of 50 industry-sponsored phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 65. This study's 8 months is below that.

Counting every sponsor, half of 209 studies reached it within 57 months; a quarter within 35 and three quarters within 92.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Sep 2026 → Jul 2026 and completion Sep 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 22, 2025
StartActual
Nov 18, 2025
Primary completionActual
Jul 21, 2026was Sep 2026
CompletionActual
Jul 21, 2026was Sep 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Sep 25, 2026
Primary completion
Sep 29, 2026→Jul 21, 2026 (actual)
Sep 25, 2026
Study completion
Sep 29, 2026→Jul 21, 2026 (actual)
Sep 25, 2026
Enrollment
10 (estimated)→6 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Recruiting→Completed
    Primary completion Sep 29, 2026→Jul 21, 2026 (now actual)
    Study completion Sep 29, 2026→Jul 21, 2026 (now actual)
    Enrollment 10 (estimated)→6 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07295951
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
Nov 18, 2025
Primary completion
Jul 21, 2026
Completion
Jul 21, 2026
Last update
Sep 25, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bleximenib

Start the discussion